President-elect Donald Trump has attempted to be more conciliatory than he was during his campaign, signaling flexibility on some of his most extreme campaign promises. For example, Trump 2.0 has been downright cuddly to pharma after frequently criticizing its pricing practices during his campaign.
A health-care plan on his transition website has no mention of high drug prices, with only vague bullet points on supporting innovative research and softening the FDA. Biopharma stocks had plunged this year due partly to fears that a Hillary Clinton presidency might usher in drug-price controls; the Nasdaq Biotech Index was down as much as 26 percent for the year the week before the election. The index spiked 9 percent on the Wednesday after Trump won the election, its biggest jump since 2008.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
